Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.
It's a single arm, open label prospective study, in which the safety and efficacy of Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T therapy are evaluated in refractory/relapsed B cell lymphoma patients.
B Cell Lymphoma
BIOLOGICAL: Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells
complete remission rate, complete remission rate after treated by CAR-T therapy, at the time point 3 months after CAR-T cell transfusion|adverse events, any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure, from the date of the start of treatment to 24 months after last patient's enrollment
progression free surviva, from date of inclusion to date of progression, relapse, or death from any cause, from the day of treatment to the date of first documented progression，up to 24 months after the last patient's enrollment|overall survival, from the date of inclusion to date of death, irrespective of cause, from the day of treatment to the date of first documented progression，up to 24 months after the last patient's enrollment|duration of the CAR-T cells in the patients, time from re-transfusion to date when the modified T cells become non-detectable., from the date of re-transfusison to 24 months after last patient's enrollment
It's a single arm, open label prospective study, in which the safety and efficacy of Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T therapy are evaluated in refractory/relapsed B cell lymphoma patients.